Original Article

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

October 6, 2011 | D. Slamon and Others

Trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar to those for an anthracycline-containing regimen, with lower rates of cardiac toxicity and secondary leukemia.